Upadacitinib
Showing 1 - 25 of 90
Upadacitinib of Enthesitis Evaluated by Ultrasound in Psoriatic
Not yet recruiting
- Psoriatic Arthritis
- Upadacitinib
-
Madrid, SpainInstituto de Investigación Sanitaria Fundación Jiménez Díaz
Nov 25, 2023
Atopic Dermatitis Trial in Roma (Upadacitinib)
Recruiting
- Atopic Dermatitis
- Upadacitinib
-
Roma, ItalyIrccs Fondazione Policlinico Gemelli
Aug 4, 2023
Vitiligo Trial (Upadacitinib, Placebo)
Not yet recruiting
- Vitiligo
- Upadacitinib
- Placebo
- (no location specified)
Nov 1, 2023
Alopecia Areata Trial (Upadacitinib, Placebo)
Not yet recruiting
- Alopecia Areata
- Upadacitinib
- Placebo
- (no location specified)
Aug 22, 2023
Hidradenitis Suppurativa Trial (Upadacitinib, Placebo)
Not yet recruiting
- Hidradenitis Suppurativa
- Upadacitinib
- Placebo
- (no location specified)
May 26, 2023
Oral Upadacitinib Tablets to Assess Adverse Events and Change in
Not yet recruiting
- Atopic Dermatitis (AD)
- (no location specified)
Jul 17, 2023
Assess Speed of Onset and Durability of Effectiveness of
Not yet recruiting
- Crohn's Disease
- (no location specified)
Jun 27, 2023
Juvenile Idiopathic Arthritis Trial (Upadacitinib, Tocilizumab)
Not yet recruiting
- Juvenile Idiopathic Arthritis
- Upadacitinib
- Tocilizumab
- (no location specified)
Nov 7, 2022
Disease Activity in Adult Ulcerative Colitis
Not yet recruiting
- Ulcerative Colitis
- (no location specified)
Aug 9, 2022
Application of N-of-1 Rheumatoid Arthritis
Not yet recruiting
- Arthritis, Rheumatoid
- Adalimumab
- +2 more
-
Boston, MassachusettsTufts Medical Center
Aug 24, 2023
Disease Activity in Adolescents and Moderate to Severe
Not yet recruiting
- Atopic Dermatitis
- (no location specified)
Jul 7, 2022
Disease Activity and Adverse Events in Adolescent and Adult
Recruiting
- Crohn's Disease
-
Toyota-shi, Aichi, Japan
- +1 more
Aug 29, 2023
Assess Real-World Effectiveness of Upadacitinib in Adult
Recruiting
- Rheumatoid Arthritis
-
Kendal, Cumbria, United Kingdom
- +2 more
Aug 8, 2022
Oral Upadacitinib Tablets to Assess Adverse Events and Change in
Recruiting
- Rheumatoid Arthritis (RA)
- +3 more
-
Bucheon, Gyeonggido, Korea, Republic of
- +3 more
Nov 8, 2022
Atopic Dermatitis Trial in Norway, Puerto Rico, United States (Upadacitinib (ABT-494))
Active, not recruiting
- Atopic Dermatitis
- Upadacitinib (ABT-494)
-
Huntington Beach, California
- +17 more
Jan 25, 2023
Rheumatoid Arthritis, JAK Inhibitor, Musculoskeletal Ultrasound Trial in Nagasaki (upadacitinib 15mg/day)
Recruiting
- Rheumatoid Arthritis
- +3 more
- upadacitinib 15mg/day
-
Nagasaki, JapanNagasaki University Hospital
Nov 24, 2021
Atopic Dermatitis (AD) Trial (Upadacitinib)
No longer available
- Atopic Dermatitis (AD)
- Upadacitinib
- (no location specified)
Aug 2, 2021
Upadacitinib in Adult Hungarian Moderate to Severe Rheumatoid
Recruiting
- Rheumatoid Arthritis
-
Szeged, Csongrad, Hungary
- +7 more
Nov 9, 2022
Disease Activity and Adverse Events of Upadacitinib in Adult
Recruiting
- Ulcerative Colitis
-
Ciudad Autonoma de Buenos Aire, Ciuadad Autonoma De Buenos Aires, Argentina
- +13 more
Aug 16, 2022
Ulcerative Colitis Acute Trial in Ann Arbor (Cyclosporine Injection (IV), Cyclosporine Oral Product, Upadacitinib Extended
Not yet recruiting
- Ulcerative Colitis Acute
- Cyclosporine Injection (IV)
- +4 more
-
Ann Arbor, MichiganUniversity of Michigan
May 6, 2023
Molecular Signatures in Inflammatory Skin Disease
Recruiting
- Atopic Dermatitis
- Psoriasis
- Ustekinumab
- +9 more
-
Kiel, GermanyDepartment of Dermatology, University Hospital Schleswig Holstei
Jul 16, 2022
Atopic Dermatitis (AD) Trial (Upadacitinib, Placebo for Upadacitinib)
Withdrawn
- Atopic Dermatitis (AD)
- Upadacitinib
- Placebo for Upadacitinib
- (no location specified)
Apr 7, 2021
Hidradenitis Suppurativa (HS) Trial in Worldwide (Upadacitinib, Placebo Upadacitinib)
Completed
- Hidradenitis Suppurativa (HS)
- Upadacitinib
- Placebo Upadacitinib
-
Phoenix, Arizona
- +25 more
Mar 22, 2022
Atopic Dermatitis Trial in Japan (Upadacitinib, Placebo for upadacitinib, Topical Corticosteroids (TCS))
Completed
- Atopic Dermatitis
- Upadacitinib
- +2 more
-
Ichinomiya-shi, Aichi, Japan
- +42 more
Sep 6, 2022